Novartis | NVS - Trade Creditors


Novartis reported $4.24B in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
AbbVie USD 33.3B 29.71B Jun/2026
Amgen USD 20.83B 17.97B Sep/2026
AstraZeneca USD 23.57B 679M Sep/2026
Bausch Health Companies USD 517M 76M Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Canopy Growth CAD 28.61M 6.21M Jun/2026
Corcept Therapeutics USD 21.92M 7.01M Sep/2026
Drreddys Laboratories INR 36.08B 13.72B Sep/2026
Eli Lilly USD 5.79B 319M Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
GlaxoSmithKline GBP 15.63B 1.29B Sep/2026
Glaxosmithkline GBP 15.63B 1.3B Sep/2026
J&J USD 9.32B 94M Sep/2026
Merck USD 5.03B 1.2B Sep/2026
Novartis USD 4.24B 15M Sep/2026
Novartis USD 4.24B 79M Sep/2026
Pacira USD 17.5M 4K Sep/2026
Perrigo USD 390.5M 9.9M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
Phibro Animal Health USD 136.45M 9.13M Sep/2026
Prestige Brands USD 44.02M 7.17M Sep/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sanofi EUR 24.55B 957M Sep/2026
Sanofi EUR 23.6B 888M Jun/2026
Supernus Pharmaceuticals USD 8.52M 2.92M Sep/2026
Zoetis USD 419M 33M Sep/2026